---
figid: PMC3141822__nihms309440f4
figlink: /pmc/articles/PMC3141822/figure/F4/
number: F4
caption: Possible mechanisms that sorafenib and PI-103 differentially inhibits and
  activates key kinases in the Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. (A) In the
  absence of added inhibitors, EGF/EGFR signaling activates Ras/Raf/MAPK and PI3K/AKT/mTOR
  pathways. Activation of S6K in the PI3K/AKT/mTOR pathway may induce feedback inhibition
  on Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. (B) When sorafenib is added, sorafenib
  directly or indirectly inhibits Raf, MEK and ERK (shown by rectangles). Sorafenib
  may activate HGF/HGFR signaling via activation of PI3K, thus further activating
  AKT, mTOC1 and mTORC2 and S6K based on the activated levels after EGF stimulation
  (shown by ovals). Activation of S6K still causes feedback inhibition on both pathways.
  (C) Addition of PI-103 directly inhibits PI3K, mTORC1 and mTORC2. PI-103 indirectly
  inhibits AKT and S6K in the PI3K/AKT/mTOR pathway (shown by rectangles). Inhibition
  of S6K eliminates the feedback inhibition effect of S6K, thus increasing the signal
  towards the Ras/Raf/MAPK pathway and further stimulated the Ras, Raf, MEK and ERK
  phosphorylation based on the activated levels after EGF stimulation (shown by ovals).
  (D) Combination of sorafenib and PI-103 blocks EGF stimulated Ras/Raf/MAPK and PI3K/AKT/mTOR
  pathways. Therefore the combination of sorafenib and PI-103 may have an advantage
  over mono-drug treatment in HCC therapy.
pmcid: PMC3141822
papertitle: PI-103 and Sorafenib Inhibit Hepatocellular Carcinoma Cell Proliferation
  by Blocking Ras/Raf/MAPK and PI3K/AKT/mTOR Pathways.
reftext: ROBERTO GEDALY, et al. Anticancer Res. ;30(12):4951-4958.
pmc_ranked_result_index: '72005'
pathway_score: 0.775878
filename: nihms309440f4.jpg
figtitle: Possible mechanisms that sorafenib and PI-103 differentially inhibits and
  activates key kinases in the Ras/Raf/MAPK and PI3K/AKT/mTOR pathways
year: ''
organisms: Homo sapiens
ndex: 5bc71900-deab-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3141822__nihms309440f4.html
  '@type': Dataset
  description: Possible mechanisms that sorafenib and PI-103 differentially inhibits
    and activates key kinases in the Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. (A)
    In the absence of added inhibitors, EGF/EGFR signaling activates Ras/Raf/MAPK
    and PI3K/AKT/mTOR pathways. Activation of S6K in the PI3K/AKT/mTOR pathway may
    induce feedback inhibition on Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. (B) When
    sorafenib is added, sorafenib directly or indirectly inhibits Raf, MEK and ERK
    (shown by rectangles). Sorafenib may activate HGF/HGFR signaling via activation
    of PI3K, thus further activating AKT, mTOC1 and mTORC2 and S6K based on the activated
    levels after EGF stimulation (shown by ovals). Activation of S6K still causes
    feedback inhibition on both pathways. (C) Addition of PI-103 directly inhibits
    PI3K, mTORC1 and mTORC2. PI-103 indirectly inhibits AKT and S6K in the PI3K/AKT/mTOR
    pathway (shown by rectangles). Inhibition of S6K eliminates the feedback inhibition
    effect of S6K, thus increasing the signal towards the Ras/Raf/MAPK pathway and
    further stimulated the Ras, Raf, MEK and ERK phosphorylation based on the activated
    levels after EGF stimulation (shown by ovals). (D) Combination of sorafenib and
    PI-103 blocks EGF stimulated Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Therefore
    the combination of sorafenib and PI-103 may have an advantage over mono-drug treatment
    in HCC therapy.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - RAF1
  - PIK3CG
  - MET
  - PIK3R3
  - PIK3CB
  - PIK3CA
  - PIK3CD
  - MAPK3
  - PIK3R4
  - AKT3
  - KRAS
  - ARAF
  - MAP2K2
  - RICTOR
  - EGF
  - MAP2K1
  - MAPK1
  - PIK3R5
  - BRAF
  - HRAS
  - AKT2
  - NRAS
  - MTOR
  - MLST8
  - EGFR
  - PIK3R6
  - AKT1
  - MAPKAP1
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: HGFR
  symbol: HGFR
  source: hgnc_alias_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: RICTOR
  entrez: '253260'
- word: EGF/EGFR
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MLST8
  entrez: '64223'
- word: EGF/EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MAPKAP1
  entrez: '79109'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC3141822__F4
redirect_from: /figures/PMC3141822__F4
figtype: Figure
---
